Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
- PMID: 12915557
- PMCID: PMC187406
- DOI: 10.1128/jvi.77.17.9422-9430.2003
Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
Abstract
Naturally occurring polymorphisms in the protease of human immunodeficiency virus type 1 (HIV-1) subtype C would be expected to lead to adaptive (compensatory) changes in protease cleavage sites. To test this hypothesis, we examined the prevalences and patterns of cleavage site polymorphisms in the Gag, Gag-Pol, and Nef cleavage sites of C compared to those in non-C subtypes. Codon-based maximum-likelihood methods were used to assess the natural selection and evolutionary history of individual cleavage sites. Seven cleavage sites (p17/p24, p24/p2, NC/p1, NC/TFP, PR/RT, RT/p66, and p66/IN) were well conserved over time and in all HIV-1 subtypes. One site (p1/p6(gag)) exhibited moderate variation, and four sites (p2/NC, TFP/p6(pol), p6(pol)/PR, and Nef) were highly variable, both within and between subtypes. Three of the variable sites are known to be major determinants of polyprotein processing and virion production. P2/NC controls the rate and order of cleavage, p6(gag) is an important phosphoprotein required for virion release, and TFP/p6(pol), a novel cleavage site in the transframe domain, influences the specificity of Gag-Pol processing and the activation of protease. Overall, 58.3% of the 12 HIV-1 cleavage sites were significantly more diverse in C than in B viruses. When analyzed as a single concatenated fragment of 360 bp, 96.0% of group M cleavage site sequences fell into subtype-specific phylogenetic clusters, suggesting that they coevolved with the virus. Natural variation at C cleavage sites may play an important role, not only in regulation of the viral cycle but also in disease progression and response to therapy.
Figures



Similar articles
-
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.Virology. 2002 Jan 5;292(1):137-49. doi: 10.1006/viro.2001.1184. Virology. 2002. PMID: 11878916
-
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266. Virology. 1996. PMID: 8638406
-
New findings in cleavage sites variability across groups, subtypes and recombinants of human immunodeficiency virus type 1.PLoS One. 2014 Feb 7;9(2):e88099. doi: 10.1371/journal.pone.0088099. eCollection 2014. PLoS One. 2014. PMID: 24516589 Free PMC article.
-
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1209-13. doi: 10.1089/08892220050116970. AIDS Res Hum Retroviruses. 2000. PMID: 10957718
-
HIV-1 replication.Somat Cell Mol Genet. 2001 Nov;26(1-6):13-33. doi: 10.1023/a:1021070512287. Somat Cell Mol Genet. 2001. PMID: 12465460 Review.
Cited by
-
The N-end rule and retroviral infection: no effect on integrase.Virol J. 2013 Jul 13;10:233. doi: 10.1186/1743-422X-10-233. Virol J. 2013. PMID: 23849394 Free PMC article.
-
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56. doi: 10.1128/AAC.02682-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26833162 Free PMC article. Clinical Trial.
-
A substrate selected by phage display exhibits enhanced side-chain hydrogen bonding to HIV-1 protease.Acta Crystallogr D Struct Biol. 2018 Jul 1;74(Pt 7):690-694. doi: 10.1107/S2059798318006691. Epub 2018 Jun 27. Acta Crystallogr D Struct Biol. 2018. PMID: 29968678 Free PMC article.
-
Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.J Virol. 2006 Jun;80(12):6136-45. doi: 10.1128/JVI.02212-05. J Virol. 2006. PMID: 16731952 Free PMC article.
-
Human Immunodeficiency Virus Gag and protease: partners in resistance.Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63. Retrovirology. 2012. PMID: 22867298 Free PMC article. Review.
References
-
- Anisimova, M., J. P. Bielawski, and Z. Yang. 2001. Accuracy and power of the likelihood ratio test in detecting adaptive molecular evolution. Mol. Biol. Evol. 18:1585-1592. - PubMed
-
- Ball, S. C., A. Abraha, K. R. Collins, A. J. Marozsan, H. Baird, M. E. Quinones-Mateu, A. Penn-Nicholson, M. Murray, N. Richard, M. Lobritz, P. A. Zimmerman, T. Kawamura, A. Blauvelt, and E. J. Arts. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77:1021-1038. - PMC - PubMed
-
- Billich, S., M. T. Knoop, J. Hansen, P. Strop, J. Sedlacek, R. Mertz, and K. Moelling. 1988. Synthetic peptides as substrates and inhibitors of human immunodeficiency virus-1 protease. J. Biol. Chem. 263:17905-17908. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials